Get started
REGENERON PHARMACEUTICALS INCREGENERON PHARMACEUTICALS INCREGENERON PHARMACEUTICALS INC

REGENERON PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

RGO chart


Full chart

Key facts today

The FDA revoked the emergency use authorization for Regeneron Pharmaceuticals' REGEN-COV COVID-19 treatment due to its expired shelf life and no patient use for over a year.
Analyze the impactAnalyze the impact

RGO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪68.92 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
19.943
Basic EPS (TTM)
36.632 CHF
Net income (FY)
‪3.33 B‬ CHF
Revenue (FY)
‪11.04 B‬ CHF
Shares float
‪105.92 M‬
Beta (1Y)
0.84

Employees


Employees (FY)
‪13.45 K‬
Change (1Y)
‪+1.6 K‬ +13.49%
Revenue / Employee (1Y)
‪821.10 K‬ CHF
Net income / Employee (1Y)
‪247.49 K‬ CHF

About Regeneron Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
regeneron.com
Founded
1988
FIGI
BBG006TLTK93
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RGO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

RGO highest yielding bonds


REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050
Yield to maturity
7.46%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030
Yield to maturity
5.66%
Maturity date
Sep 15, 2030

Explore more bonds 

Sparks


Curated watchlists where RGO is featured.

See all sparks 

Frequently Asked Questions


The current price of RGO is 670.852 CHF — it has decreased by −6.98% in the past 24 hours. Watch REGENERON PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange REGENERON PHARMACEUTICALS INC stocks are traded under the ticker RGO.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC future price: according to them, RGO price has a max estimate of 1,105.82 CHF and a min estimate of 507.96 CHF. Watch RGO chart and read a more detailed REGENERON PHARMACEUTICALS INC stock forecast: see what analysts think of REGENERON PHARMACEUTICALS INC and suggest that you do with its stocks.
RGO reached its all-time high on Jun 26, 2024 with the price of 952.146 CHF, and its all-time low was 531.540 CHF and was reached on Oct 26, 2021. View more price dynamics on RGO chart.
See other stocks reaching their highest and lowest prices.
RGO stock is 7.50% volatile and has beta coefficient of 0.84. Track REGENERON PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS INC there?
Today REGENERON PHARMACEUTICALS INC has the market capitalization of ‪68.92 B‬, it has increased by 0.85% over the last week.
Yes, you can track REGENERON PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMACEUTICALS INC is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
RGO earnings for the last quarter are 10.56 CHF per share, whereas the estimation was 9.91 CHF resulting in a 6.54% surprise. The estimated earnings for the next quarter are 10.10 CHF per share. See more details about REGENERON PHARMACEUTICALS INC earnings.
REGENERON PHARMACEUTICALS INC revenue for the last quarter amounts to ‪3.15 B‬ CHF, despite the estimated figure of ‪3.11 B‬ CHF. In the next quarter, revenue is expected to reach ‪3.36 B‬ CHF.
RGO net income for the last quarter is ‪1.14 B‬ CHF, while the quarter before that showed ‪1.29 B‬ CHF of net income which accounts for −11.78% change. Track more REGENERON PHARMACEUTICALS INC financial stats to get the full picture.
No, RGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 24, 2024, the company has ‪13.45 K‬ employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC EBITDA is ‪3.90 B‬ CHF, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMACEUTICALS INC financial statements.
Like other stocks, RGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMACEUTICALS INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMACEUTICALS INC stock shows the strong sell signal. See more of REGENERON PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.